Home › Chronic Myelomonocytic Leukemia › New York
Chronic Myelomonocytic Leukemia clinical trials in New York
8 studies for Chronic Myelomonocytic Leukemia are looking for participants at sites in New York.
Cities in New York
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- Mount Sinai Hospital, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07143669Pacritinib in CMML
- The Mount Sinai Hospital, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06159491Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
- Wilmot Cancer Institute, University of Rochester, Rochester
RecruitingEarly phase 1
Ages 18 to 75 · All sexes · Updated Jun 3, 2026 · NCT03964506A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Roswell Park Comprehensive Cancer Center, Buffalo
- New York University Langone Hospital - Long Island, Mineola
- Perlmutter Cancer Center - 34th Street, New York
- and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Memorial Sloan Kettering, New York
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Mar 16, 2026 · NCT06994676Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- Montefiore Medical Center, The Bronx
- White Plains Hospital, White Plains
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 5, 2026 · NCT05184842Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.